Navigation Links
Stem Cell Therapy to Skyrocket by 2017
Date:9/13/2007

Although still in its infancy, stem cell therapy market to grow rapidly

over next decade

WALTHAM, Mass., Sept. 13 /PRNewswire/ -- Millennium Research Group (MRG) has conducted a detailed analysis of the stem cell therapy market in its US Markets for Stem Cell Therapies 2007 report. The analysis reveals that although the market for stem cell therapies is in its infancy, it will grow rapidly as products are approved in the US. Today, only two products are on the market, but by 2017, almost 90 are expected to be available.

Stem cells have regenerative capabilities, and promise lasting treatments for chronic disorders and potential cures for currently 'incurable' diseases. In 2007, the US stem cell therapies market earned over $25 million in revenues, with only two orthopedic products available in the US-Osiris Therapeutics' Osteocel, and Blackstone Medical's Trinity. Aside from these two products, the development of the US market for stem cell therapies is largely dependent on the success of clinical trials, regulatory approval, and public acceptance. The first products in the cardiovascular, diabetes, neurological, and tissue and organ stem cell therapy markets are expected to enter the market between 2009 and 2013. The entry of these products will open up a new realm of treatable disorders, offering hope to patients and vast market potential.

"This market has almost everything going its way", says Chris Schutz, senior analyst at MRG. "The big question mark however is the political and public support. The prevalence of potentially treatable disorders, unmet medical needs, rising health care costs, growth in the aging population, and the success of the first stem cell therapy products are all factors that will drive this market upward through 2017."

The US Markets for Stem Cell Therapies 2007 report includes coverage of companies offering or developing products for the stem cell therapy market, including Aastrom Biosciences, Advanced Cell Technologies, Arteriocyte, Blackstone Medical, Cytori Therapeutics, Geron, Harvest Technologies, International Stem Cell Corporation, and Osiris Therapeutics.

About Stem Cells

Stem cells are primal cells that are derived from highly proliferative tissues. These cells are precursors to every organ, tissue, and cell in the human body. Because of their universality and ability to repair or replace damaged tissue, stem cells have the potential to cure injuries and diseases such as orthopedic degenerative disease, cardiovascular disease, diabetes, neurological disease, cancer, retinal disease, and other chronic and autoimmune disorders.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Millennium Research Group
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Genesis of Gendicine: The Story Behind the First Gene Therapy
2. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
3. TomoTherapy opens technical training center
4. TomoTherapy raises $223 million in IPO
5. TomoTherapy revises IPO money target
6. Stem cell therapy shows visionary promise
7. Hospital named for Madame Curie installs TomoTherapy system
8. TomoTherapy files registration statement for IPO
9. TomoTherapy to sell medical devices in India
10. TomoTherapy sees sustained market advantage
11. Mirus granted European patent for gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... ... today announced safety software company AB Cube has joined its eHealth ... to advance technology innovation across life sciences and healthcare. Under the partnership, ...
(Date:7/17/2017)... ... 2017 , ... Panitch Schwarze Belisario & Nadel ... (Biomedical Innovation Group) annual meeting in China. , This year’s meeting, held June ... therapy, a rapidly developing highly personalized anti-cancer technology that involves removing some of ...
(Date:7/16/2017)... ... July 16, 2017 , ... OHAUS Corporation, a leading ... of its new line of Rocking and Waving Shakers today. , Five New ... analog and digital) for laboratory applications in a variety of environmental conditions. Rocking ...
(Date:7/14/2017)... ... ... Sonic Manufacturing Technologies is proud to be an ... on its roof top. “We will be independent of the grid and completely ... company’s proud history of social responsibility and participation in the preservation of Silicon ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
(Date:3/22/2017)... YORK , March 21, 2017 ... Marketing Cloud used by retailers such as 1-800-Flowers ... its platform — Product Recommendations and Replenishment. Using Optimove,s ... give more personalized product and replenishment recommendations to ... but also on predictions of customer intent drawn ...
Breaking Biology News(10 mins):